COMMUNIQUÉS West-GlobeNewswire

Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist
05/11/2026
CMS establishes $314.54 reimbursement rate for CPT code 97610 for 2027, an approximately 21% reduction vs 2026 rate of $397.81 2027 Hospital outpatient rate for 97610 code set at $235.04, an approximately 15% increase [...]
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
05/11/2026
New investor presentation outlines scientific rationale for combining Ampligen’s immune-stimulating activity with daraxonrasib’s targeted RAS inhibition to potentially prolong clinical benefit Previously reported [...]
Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry
05/11/2026
The 6-month target lesion primary patency (TLPP) 1 and access circuit primary patency (ACPP) 2 for patients in the arteriovenous fistula (AVF) cohort were 92.7% and 76.7%, respectively The real-world patency results [...]
Regen BioPharma, Inc. Provides Shareholder Update on Company’s Activities and Direction
05/11/2026
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) Update on Regen’s recent activities (i.e.: debt payoff, financing, potential joint ventures): The Company has recently paid off [...]
GenomOncology Integrates ARUP Laboratories’ Jalapheno Phenotype-Matching Tool Into GO Pathology Workbench Under Multiyear Exclusive Agreement
05/11/2026
Gene-level phenotype-matching scores from patient Human Phenotype Ontology (HPO) terms now feed directly into variant prioritization for rare disease exome, genome, and large-panel germline testing, alongside new [...]
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
05/11/2026
First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD) Presentation to take place on Monday, [...]
Resolution Therapeutics Announces Positive Interim Phase I/II EMERALD Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease
05/11/2026
Six-month interim data showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation versus an external control RTX001 was well tolerated with no infusion-related serious adverse reactions; [...]
CurePSP Names First Recipients of Biomarker Accelerator Program, Awarding Its Largest Research Grants to Date
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CurePSP has awarded more than $1.4 million through its Biomarker Accelerator Program to three researchers working to find reliable biomarkers for progressive supranuclear [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026 , Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Resalis Therapeutics Announces First-in-Human Data for RES-010 Demonstrating Safety and Tolerability with Early Weight Loss Signals
05/11/2026
The completed Phase 1a study data in healthy volunteers showed early signs of pharmacodynamic activity supporting further clinical evaluation of RES-010 The Phase 1b study in healthy overweight and moderately obese [...]
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting
05/11/2026
Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours VANCOUVER, British Columbia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS [...]
2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint
05/11/2026
BEIJING, Nov. 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that results from [...]
Arcoma AB (publ) offentliggör att Eiffel Investment Group passerat 10 procent av aktierna och rösterna.
05/11/2026
PRESSRELEASE 2026-11-05 Arcoma AB (publ) offentliggör att Eiffel Investment Group passerat 10 procent av aktierna och rösterna. Arcoma AB (publ) ("Arcoma") har mottagit information från Eiffel Investment Group om att de [...]
LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook
05/11/2026
SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third [...]
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
05/11/2026
- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat [...]
Privia Health Reports Strong Third Quarter and Year-to-Date 2026 Results
05/11/2026
YTD’26 Net Income of $25.6M, +85.9% from YTD’25 YTD’26 Adjusted EBITDA of $114.7M, +21.9% from YTD’25 Full-Year 2026 Guidance Raised to Above High End for All Key Financial Metrics Expands VBC Footprint with Acquisition [...]
ENOVIS Announces Third Quarter 2026 Results
05/11/2026
Third-quarter sales growth of 2% on a reported basis, 5% organic Third-quarter Reconstructive sales growth of 6% on a reported and organic basis Raising full-year 2026 guidance for adjusted EBITDA and adjusted EPS Board [...]
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Strong U.S. demand for AQVESME in [...]
Oxford Brain Diagnostics Wins 2026 CNS Summit Innovation Showcase
05/11/2026
MRI-based CDM technology identified patients with MCI who progressed to dementia three times faster, offering drug developers a new tool for patient selection OXFORD, United Kingdom, Nov. 05, 2026 (GLOBE NEWSWIRE) -- [...]

Pages